 |
|
|
|
|
FDA Mandates Stronger Warning on Asthma Drug Xolair
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 "That's a little disturbing, but most asthmatics have EpiPens to use if they were to experience a life-threatening allergic reaction," Horovitz said.
And Yucynthia Jean-Louis, president of the Asthma and Allergy Foundation of America (AAFA), said the group recognizes the importance of new treatments such as Xolair in fighting moderate to severe asthma. "AAFA encourages the companies and the FDA to continue to work together to assure a product label that is in the best interest of patients," she said.
More information
Text Continues Below
For more details, visit the U.S. Food and Drug Administration.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 2/21/2007
|
|
SOURCES: Andrew Colin, M.D., professor, pediatrics, and director, pediatric pulmonology, University of Miami Miller School of Medicine; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; David Weldon, M.D., assistant professor, internal medicine, Texas A&M Health Science Center College of Medicine, and director, Allergy and Pulmonary Lab Services, Scott & White Clinic, College Station, Texas; Yucynthia Jean-Louis, president, Asthma and Allergy Foundation of America
|
.gif)
